메뉴 건너뛰기




Volumn 7, Issue 10, 2008, Pages 990-992

Etanercept in therapy multiresistant overlapping pityriasis lichenoides

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; IMMUNOGLOBULIN G; NONSTEROID ANTIINFLAMMATORY AGENT; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

EID: 59049086637     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (9)

References (8)
  • 3
    • 34347228129 scopus 로고    scopus 로고
    • Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: An updated review
    • DOI 10.2165/00128071-200708030-00002
    • Romero-Mate A, Garcia-Donoso C, Cordoba-Guijarro S. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review. Am J Clin Dermatol. 2007;8:143-155. (Pubitemid 46998542)
    • (2007) American Journal of Clinical Dermatology , vol.8 , Issue.3 , pp. 143-155
    • Romero-Mate, A.1    Garcia-Donoso, C.2    Cordoba-Guijarro, S.3
  • 4
    • 33845422588 scopus 로고    scopus 로고
    • Off-Label Uses of Biologic Agents in Dermatology: A 2006 Update
    • DOI 10.1016/j.sder.2006.08.006, PII S108556290600071X, Advances in Dermatology and Internal Medicine
    • Kerns MJ, Graves JE, Smith DI, Heffernan MP. Off-label uses of biologic agents in dermatology: a 2006 update. Semin Cutan Med Surg. 2006;25:226-240. (Pubitemid 44894975)
    • (2006) Seminars in Cutaneous Medicine and Surgery , vol.25 , Issue.4 , pp. 226-240
    • Kerns, M.Jo.J.1    Graves, J.E.2    Smith, D.I.3    Heffernan, M.P.4
  • 5
    • 34250352810 scopus 로고    scopus 로고
    • Etanercept and recalcitrant acrodermatitis continua of Hallopeau
    • Nikkels AF, Piérard GE. Etanercept and recalcitrant acrodermatitis continua of Hallopeau. J Drugs Dermatol. 2006;5:705-706.
    • (2006) J Drugs Dermatol , vol.5 , pp. 705-706
    • Nikkels, A.F.1    Piérard, G.E.2
  • 6
    • 33845685405 scopus 로고    scopus 로고
    • Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2)
    • DOI 10.1016/j.jaad.2006.07.019, PII S0190962206020858
    • Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept. J Am Acad Dermatol. 2007;56:e55-79. (Pubitemid 44969298)
    • (2007) Journal of the American Academy of Dermatology , vol.56 , Issue.1
    • Graves, J.E.1    Nunley, K.2    Heffernan, M.P.3
  • 8
    • 45049083149 scopus 로고    scopus 로고
    • Mechanism of action, pharmacokinetics, and drug interactions of etanercept in dermatology
    • Papp KA, Keystone EC, Shear NH. Mechanism of action, pharmacokinetics, and drug interactions of etanercept in dermatology. J Cutan Med Surg. 2007;11: Suppl 1:S3-13.
    • (2007) J Cutan Med Surg , vol.11 , Issue.SUPPL. 1
    • Papp, K.A.1    Keystone, E.C.2    Shear, N.H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.